|Chemical and physical data|
|Molar mass||379.88 g·mol−1|
|(what is this?)|
Licofelone is a dual COX/LOX inhibitor that was studied in clinical trials as a treatment for osteoarthritis and which was under development by Merckle GmbH with partners Alfa Wassermann and Lacer.
Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-lipoxygenase (5-LOX) may reduce the gastrointestinal toxicity associated with other nonsteroidal anti-inflammatory drugs (NSAID), which only inhibit cyclooxygenase (COX). Licofelone is the first drug to inhibit both.
- Fischer L, Hornig M, Pergola C, et al. (October 2007). "The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products". British Journal of Pharmacology. 152 (4): 471–80. doi:10.1038/sj.bjp.0707416. PMC . PMID 17704828.
- Vidal C, Gómez-Hernández A, Sánchez-Galán E, et al. (January 2007). "Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 108–16. doi:10.1124/jpet.106.110361. PMID 17015640.
- Alvaro-Gracia JM (February 2004). "Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis". Rheumatology (Oxford, England). 43 Suppl 1 (90001): i21–5. doi:10.1093/rheumatology/keh105. PMID 14752172.
- "Licofelone – Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis". Retrieved January 12, 2018.
- Wildi, L. M; Raynauld, J.-P; Martel-Pelletier, J; Abram, F; Dorais, M; Pelletier, J.-P (2010). "Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: Results from a randomised controlled clinical trial using MRI". Annals of the Rheumatic Diseases. 69 (12): 2118. doi:10.1136/ard.2009.127993. PMID 20610445.